Clinical Trial Update: QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating QL1706 plus chemotherapy for borderline resectable esophageal cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• QL1706

Snippet

Sponsor: Ruijin Hospital | Conditions: Esophageal Cancer | Phase 2 | Status: NOT_YET_RECRUITING